The landscape of reimbursement policy underwent significant transformations in 2025, marked by new regulations and shifting financial pressures. Central themes included the “One Big Beautiful Bill,” the Most Favored Nation drug policy, and various reforms initiated by the previous administration. These changes generated considerable uncertainty among payers, providers, and patients alike. However, recent agreements regarding glucagon-like peptide 1 (GLP-1) therapies offered a glimmer of hope for enhancing affordability and access to essential treatments.
This article outlines the five most impactful reimbursement articles of 2025, reflecting the ongoing challenges and developments in the healthcare reimbursement arena.
Medicaid Work Requirements Impact Millions
The introduction of House Rule 1, known as the “One Big Beautiful Bill Act,” in July 2025, marked a pivotal moment for Medicaid. This legislation mandated that beneficiaries verify a minimum of 80 activity hours per month every six months to maintain their coverage. The Congressional Budget Office projected that up to 5.2 million adults might lose their Medicaid coverage by 2034. Such drastic changes pose serious risks, including limited access to healthcare and deteriorating health outcomes. Rural and safety-net hospitals, which heavily rely on Medicaid funding, could face significant financial strain. The potential loss of coverage threatens to destabilize healthcare access for vulnerable populations, particularly children and families.
Most Favored Nation Drug Pricing: Progress and Concerns
The Most Favored Nation (MFN) drug pricing policy, championed by the Trump administration, continued to evolve throughout 2025. During a webinar hosted by MJH Life Sciences®, experts expressed concerns about unresolved operational and legal details that create uncertainty for manufacturers, payers, and patients. Two proposed demonstration models, GLOBE and GUARD, were under review. Panelists highlighted the rapid growth in direct-to-consumer drug fulfillment and raised alarms about possible spillover effects on Medicaid and 340B pricing. Experts suggested that the potential for Medicaid savings under the MFN policy remains limited, necessitating a careful evaluation of its broader implications.
Uncertainty Around ACA Subsidies Post-Government Shutdown
The conclusion of the federal government shutdown in November 2025 brought temporary relief, but the future of enhanced Affordable Care Act (ACA) subsidies remained unresolved. Despite Senate Republicans signaling willingness to vote on extending these subsidies, House Republicans had not made a commitment. This uncertainty threatened to increase insurance costs for millions of marketplace enrollees, with potential premium hikes of over 100% for low-income patients if subsidies were allowed to expire. Policy analysts warned that failure to extend these subsidies could exacerbate uninsurance rates, especially among older adults and those with chronic health conditions, compounding the adverse effects of recent Medicaid cuts.
The MFN Order: A Double-Edged Sword for Innovation?
Experts have indicated that the MFN order could drastically alter the US drug pricing framework by introducing “voluntary” manufacturer agreements and the threat of tariffs to align prices more closely with international benchmarks. During the MJH Life Sciences® webinar, concerns were raised about the potential dampening of investment incentives, particularly in oncology, where the high failure rates of treatments require predictable revenue to sustain innovation. While proponents argue that the MFN order could lower costs for some patients, the complexities of global pricing, legal uncertainties, and the risk of market disruptions through tariffs could ultimately restrict access and destabilize the biopharma ecosystem.
Major Price Reductions for GLP-1 Therapies
In a significant development for weight management, the White House announced pricing agreements with Eli Lilly and Novo Nordisk in November 2025. These agreements aim to substantially lower costs for GLP-1 therapies, including semaglutide and tirzepatide, for Medicare, Medicaid, and patients purchasing through the new TrumpRx platform. Under these deals, the monthly prices for semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound) are expected to fall to around $245 for public programs and $350 through TrumpRx. Additionally, both companies committed to aligning future products with MFN pricing and providing extra discounts on insulin and other chronic disease medications.
Conclusion
The reimbursement landscape in 2025 reflects a delicate balance between regulatory changes, market pressures, and the need for patient access to essential therapies. As the year progresses, ongoing discussions around Medicaid reforms, drug pricing policies, and ACA subsidies will play a crucial role in shaping the future of healthcare in the United States. Stakeholders must remain vigilant and adaptable to navigate this evolving environment successfully.
- The introduction of work requirements may impact millions of Medicaid beneficiaries.
- The MFN drug pricing policy continues to raise concerns about its operational and legal details.
- Uncertainty surrounding ACA subsidies could lead to increased insurance costs for vulnerable populations.
- Investment in drug innovation may be threatened by new pricing policies.
- Recent agreements on GLP-1 therapies signify potential relief for patients facing high drug costs.
Read more → www.ajmc.com